Atlanta, GA, April 25, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded its partnership with a 5 facility, 700-bed Oracle EHR based health system. The system has been using RevID’s automated charge reconciliation for more than 2 years and has elected to add eValuator’s code auditing technology for improved pre-bill revenue integrity.
Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. RevID’s automated charge reconciliation and eValuator’s AI-enhanced pre-bill code auditing ensure that providers can accurately capture, bill and ultimately be paid for all the care they provide, while avoiding denials.
“We are ecstatic to be able to help our client expand the capabilities of their talented team to ensure accurate compensation for all of the care provided at their world-class healthcare facilities” stated Ben Stilwill, President and Chief Executive Officer, Streamline. “We look forward to leveraging the synergistic impact of RevID’s charge reconciliation and eValuator’s pre-bill code auditing technology in one health system to improve their revenue cycle.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
Contact
Jacob Goldberger
Vice President of Finance
303.887.9625
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.59 |
Daily Change: | -0.02 -0.55 |
Daily Volume: | 8,872 |
Market Cap: | US$15.330M |
December 18, 2024 December 16, 2024 October 08, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load